The recent matchmaking round by the National Institutes of Health (NIH), which awarded $12.7 million from its Common Fund for nine cooperative agreements between big pharmas and academic research institutions, is one of the latest and potentially most ambitious initiatives to repurpose failed compounds. Read More
Diabetic pumps work well for delivering insulin to reduce blood sugar levels, but insulin is only one half of the blood sugar regulation that the pancreas is responsible for. In healthy individuals, the organ also releases glucagon, a hormone responsible for signaling to the liver to act in the opposite direction, raising blood sugar levels. Read More
Heart disease, according to the Centers for Disease Control and Prevention (CDC), is the leading cause of death for both men and women. With so many Americans succumbing to the disease every year it is not surprising that a significant number of biopharmaceutical companies are concentrating their efforts on developing new therapies targeting various cardiovascular disorders. A new report from the Pharmaceutical Research and Manufacturers of America (PhRMA) has identified 215 potential therapies currently in the pipeline indicated for heart disease and stroke. Read More
